Thyroxine glucuronide | 21462-56-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Thyroxine glucuronide
• 英文别名: (2S,3S,4S,5R)-6-[4-[4-[(2S)-2-amino-2-carboxyethyl]-2,6-diiodophenoxy]-2,6-diiodophenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
• CAS: 21462-56-6
• 化学式: C₂₁H₁₉I₄NO₁₀
• 分子量: 953.0
• InChiKey: RGHRJBIKIYUHEV-SGPDEFQSSA-N

物化性质

• 熔点：
  >160°C (dec.)
• 沸点：
  888.7±65.0 °C(Predicted)
• 密度：
  2.527±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜（微溶）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  189
• 氢给体数：
  6
• 氢受体数：
  11

ADMET

代谢

甲状腺素葡萄糖苷酸是甲状腺素已知的人体代谢物。

Thyroxine glucuronide is a known human metabolite of Thyroxine.

来源:NORMAN Suspect List Exchange

文献信息

• Methods for diagnosing thyroid conditions and for monitoring thyroxine therapy
  申请人：——

  公开号：US20020076827A1

  公开（公告）日：2002-06-20

  This invention provides a method of diagnosing a thyroid condition in a subject which comprises: determining the concentration of thyroid stimulating hormone in a urine sample by a method which is not a radioimmunoassay; and comparing the concentration of thyroid stimulating hormone with a urinary concentration of thyroid stimulating hormone in a normal subject; wherein: i) a concentration of thyroid stimulating hormone which is higher than the urinary concentration of thyroid stimulating hormone in the normal subject diagnoses hypothyroidism in the subject; and ii) a concentration of thyroid stimulating hormone which is lower than the urinary concentration of thyroid stimulating hormone in the normal subject diagnoses hyperthyroidism in the subject. This invention also proves a method of monitoring thyroxine therapy.

  本发明提供了一种诊断受试者甲状腺疾病的方法，该方法包括：用非放射免疫测定法测定尿样中促甲状腺激素的浓度；将促甲状腺激素的浓度与正常受试者尿液中促甲状腺激素的浓度进行比较；其中：i) 若促甲状腺激素的浓度高于正常人尿液中的促甲状腺激素浓度，则可诊断该受试者患有甲状腺功能减退症；以及 ii) 若促甲状腺激素的浓度低于正常人尿液中的促甲状腺激素浓度，则可诊断该受试者患有甲状腺功能亢进症。本发明还证明了一种监测甲状腺素治疗的方法。
• HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM
  申请人：GEHO, W., Blair

  公开号：EP0274467B1

  公开（公告）日：1992-05-20
• POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS
  申请人：SDG, Inc.

  公开号：EP0999855A1

  公开（公告）日：2000-05-17
• TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES
  申请人：SDG, INC.

  公开号：EP1005327A1

  公开（公告）日：2000-06-07
• METHOD FOR DIAGNOSING THYROID CONDITIONS AND FOR MONITORING THYROXINE THERAPY
  申请人：Biodiagnostics, Inc.

  公开号：EP1307741A1

  公开（公告）日：2003-05-07